TD Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

TD Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Hold	0	–	–	–	272
2019 Q1	–	Hold	0	–	–	–	231
2018 Q4	–	Hold	0	–	–	–	230
2018 Q3	–	Hold	0	–	–	–	211
2018 Q2	–	Hold	0	–	–	–	195
2018 Q1	–	Hold	0	–	–	–	201
2017 Q4	–	Hold	0	–	–	–	272
2017 Q3	–	Hold	0	–	–	–	278
2017 Q2	–	Hold	0	–	–	–	188
2017 Q1	–	Hold	0	–	–	–	194
2016 Q4	–	Hold	0	–	–	–	187
2016 Q3	–	Hold	0	–	–	–	185
2016 Q2	–	Hold	0	–	–	–	174
2016 Q1	–	Hold	0	–	–	–	149
2015 Q4	–	Hold	0	–	–	–	153
2015 Q3	–	Sell	-2	Closed	-$2.92K	–	164
2015 Q2	$3K	Hold	2	–	–	﹤0.01%	141
2015 Q1	$1K	Hold	2	–	–	﹤0.01%	143
2014 Q4	$2K	Hold	2	–	–	﹤0.01%	145
2014 Q3	$2K	Hold	2	–	–	﹤0.01%	144
2014 Q2	$3K	Hold	2	–	–	﹤0.01%	146
2014 Q1	$3K	Hold	2	–	–	﹤0.01%	145
2013 Q4	$3K	Hold	2	–	–	﹤0.01%	147
2013 Q3	$4K	Hold	2	–	–	﹤0.01%	169
2013 Q2	$14K	Buy	+2	New	+$15.4K	﹤0.01%	158

Other funds holding ONCT

AAM

Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Cohen Capital Management Corte Madera, California $735M AUM 36.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TD Capital Management's ONCT Position: Q2 2019 in Review

TD Capital Management held its Oncternal Therapeutics, Inc. Common Stock (ONCT) position steady in Q2 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #272.

TD Capital Management first reported a position in ONCT in Q2 2013 and has held it in 9 quarters since. The position peaked at $14K in Q2 2013. 24 funds tracked by Wall St. Rank hold ONCT as of Q2 2019.

TD Capital Management held 0 shares of Oncternal Therapeutics, Inc. Common Stock worth $0 as of Q2 2019.
TD Capital Management left its Oncternal Therapeutics, Inc. Common Stock share count unchanged in Q2 2019.
Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of TD Capital Management's portfolio in Q2 2019, its #272 holding.
TD Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 9 quarters since.
TD Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $14K in Q2 2013.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2019.

Based on TD Capital Management's 13F filing for Q2 2019, filed 9 Aug 2019.